SLC5A2 and type 2 diabetes mellitus: In 2012, the first SGLT-2 inhibitor Dapagliflozin (Fig. 1B) derived from its precursor Phlorizin (a non-specific SGLT inhibitor, Fig. 1B [8]) was approved by the European Medicines Agency (EMA) for the treatment of type 2 diabetes.